


AMENDMENTS TO AND LISTING OF CLAIMS

1. (Currently amended) A compound of formula I:




wherein

R_a is H; C₁₋₄-alkyl; or C₁₋₄-alkyl substituted by OH, NH₂, NHC₁₋₄-alkyl or N(C₁₋₄-alkyl)₂ methyl, ethyl or isopropyl;

R_b is H; halogen; C₁₋₆-alkyl; or C₁₋₆-alkoxy, Cl, methyl or ethyl; and

R is a radical of formula (a):



wherein

R₁ is ~~piperazine or 4-methyl-piperazin-1-yl~~; and


R₂ is halogen; C₁₋₄-alkyl; C₁₋₄-alkoxy; CF₃; nitrile; nitro; or amino;
or a salt thereof.

2-4. (Canceled)

5. (Previously presented) A compound according Claim 1, wherein R₂ is Cl; F; CF₃; nitrile; nitro; or amino; or a salt thereof.

6. (Previously presented) A process for the preparation of a compound of

formula I according to claim 1, which process comprises reacting a compound of formula II



wherein R_a and R_b are as defined in claim 1,
with a compound of formula III



wherein R is as defined in claim 1,
and, where required, converting the resulting compound of formula I obtained in free form to a salt form or *vice versa*, as appropriate.


7. (Previously presented) A compound of formula I of claim 1, in free form or in a pharmaceutically acceptable salt form for use as a pharmaceutical.
8. (Previously presented) A pharmaceutical composition comprising a compound of formula I of claim 1, in free form or in a pharmaceutically acceptable salt form, in association with a pharmaceutically acceptable diluent or carrier therefor.
9. (Canceled)
10. (Currently amended) A method for preventing or treating acute or chronic transplant rejection in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of

formula I of according to Claims 1 or a pharmaceutically-acceptable salt thereof.

11. (Previously presented) A method for treating acute or chronic transplant rejection, psoriasis, or uveitis, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I of claim 1 or a pharmaceutically acceptable salt thereof.

12. (Previously presented) A compound according to Claim 1 that is 3-(1H-indol-3-yl)-4-[6-(4-methyl-piperazin-1-yl)-3-trifluoromethyl-pyridin-2-yl]-pyrrole-2,5-dione, or a pharmaceutically-acceptable salt thereof.

13. (New) A compound of formula I according to Claim 1, selected from the compounds of formula A:



wherein the substituents for each compound thereof have the following values:

Compound	R _a	R _b	R ₂	R ₅	R ₆	R ₇
1	H	CH ₃	CF ₃	CH ₃	H	H
2	H	Cl	CF ₃	CH ₃	H	H
3	H	H	CF ₃	H	-CH ₂ -CH ₂ -	
4	H	CH ₃	CF ₃	H	-CH ₂ -CH ₂ -	
5	H	CH ₂ -CH ₃	CF ₃	H	-CH ₂ -CH ₂ -	
6	H	CH ₃	F	CH ₃	H	H
7	H	H	F	CH ₃	H	H
8	H	CH ₂ -CH ₃	F	CH ₃	H	H
9	H	H	Cl	CH ₃	H	H
10	H	CH ₂ -	Cl	CH ₃	H	H

		CH ₃				
11	H	CH ₃	Cl	CH ₃	H	H
12	CH ₃	H	F	CH ₃	H	H
13	H	Cl	F	CH ₃	H	H
14	H	CH ₃	H	CH ₃	H	H
15	H	H	H	CH ₃	H	H
16	H	CH ₃	CH ₃	CH ₃	H	H
17	H	H	CH ₃	CH ₃	H	H
18	CH ₃	H	CH ₃	CH ₃	H	H
19	H	CH ₃	NO ₂	CH ₃	H	H
20	CH ₃	H	NO ₂	CH ₃	H	H
21	H	H	NO ₂	CH ₃	H	H
22	CH ₃	H	NH ₂	CH ₃	H	H
23	H	CH ₃	NH ₂	CH ₃	H	H
24	H	H	NH ₂	CH ₃	H	H
25	H	H	CN	CH ₃	H	H
26	H	CH ₃	CN	CH ₃	H	H
27	CH ₃	H	CN	CH ₃	H	H

or a salt thereof.

14. (New) A compound according to Claim 13, wherein R_a is H, R_b is H, R₂ is F, R₅ is CH₃, R₆ is H and R₇ is H; or R_a is H, R_b is H, R₂ is Cl, R₅ is CH₃, R₆ is H and R₇ is H.